Trial · NCT07077525
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
NCT07077525, Phase 4, Completed, Al-Azhar University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors. Trials, record NCT07077525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07077525
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
- NCT number
- NCT07077525
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 196 participants, actual
- Lead sponsor
- Al-Azhar University
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin + Metformin, Vildagliptin + Metformin
- First posted
- 2025-07-22
- Last updated
- 2025-07-22
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of HbA1c level | 0,6 and 12 months of treatment | Measurement of serum levels of HbA1C as a percentage (%) at 0 (baseline) 6 and 12 months. Change of serum level of HbA1C due to treatments after 12 months and determine the frequency of participants achieved reduction of HbA1c level by more than 1% |
| Primary | Evaluation of serum level of FBG | 0, 6 and 12 months | Measurement of serum level of FBG as (mg/dl) at 0,6 and 12 months. Change of serum level of FBG due to treatments after 12 months |
| Primary | Evaluation of serum level of PPG | 0.6 and 12 months | Measurement of serum level of PPG as (mg/dl) at 0,6 and 12 months. Change of serum level of PPG due to treatments after 12 months |
| Secondary | Evaluation of Body mass index (BMI) | 0,6 and 12 months of treatment | Change in body mass index (kg/m2) due to different treatments from baseline to 6, and 12 months. |
| Secondary | Evaluation of serum inflammatory cytokines | 0 and 12 months of treatment | Assessment of serum level of interleukin 8 (IL8), nitric oxide (NO) and tumor necrosis factor subtype alpha (TNF-α) at baseline and 12-months post treatment |
| Secondary | Assessment of genetic variation | After 12 months of treatment | Genotyping assays among participant of study and its relation to glycemic control and other cardiovascular risk factors for certain genes SNP rs6741949 in the DPP4 gene, SNP rs6923761 in the GLP1 receptor and SNP rs2285676, in the KATP gene. |
| Secondary | Assessment of lipid profile parameters | 0, 6 and 12 months of treatment | Measurement of lipid profile parameters at 0 (baseline) 6 and 12 months. Change of lipid profile parameters due to different treatments from baseline to 12 months of treatment |
| Secondary | Assessment of a common variant, SNP rs6741949, in the DPP4 gene | After 12 months of treatment | Assessment of a common variant, SNP rs6741949, in the DPP4 gene to determine the highest frequency and responsive alleles |
| Secondary | Assessment of a common variant SNP rs6923761, in the GLP1 receptor | After 12 months of treatment | Assessment of a common variant SNP rs6923761, in the GLP1 receptor to determine the highest frequency and responsive allele. |
| Secondary | Assessment of a common variant, SNP rs2285676, in the KATP gene. | After 12 months of treatment | Assessment of a common variant, SNP rs2285676, in the KATP gene to determine the highest frequency and responsive allele. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07077525
GET https://conductscience.org/api/trials/v1/NCT07077525/registered